BioPharmSignal logoBioPharmSignal

Biotech News

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca (ERAS)ErascaConference / presentation

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of

Open original release

Related news

ERASErasca2026-05-27 12:00 EST

Erasca to Present at the Jefferies Global Healthcare Conference

ERASErasca2026-05-11 11:00 EST

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

BMYBMYBristol-Myers Squibb Company2026-05-06 10:59 EST

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

ARGXArgenx2026-05-06 20:30 EST

argenx to Present at BofA Securities 2026 Health Care Conference

KURAKura Oncology2026-05-06 11:30 EST

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

KURAKura Oncology2026-05-12 13:40 EST

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

COGTCogent Biosciences2026-05-27 12:00 EST

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

View all latest news

Erasca

Erasca is an oncology company focused on precision medicine and targeted cancer therapies. Its pipeline is built to address genetically defined tumor biology.

Recent company news

ERASErasca2026-05-27 12:00 EST

Erasca to Present at the Jefferies Global Healthcare Conference

ERASErasca2026-05-11 20:01 EST

Erasca Reports First Quarter 2026 Business Updates and Financial Results

ERASErasca2026-05-11 11:00 EST

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

ERASErasca2026-05-06 12:00 EST

Erasca to Present at the Bank of America Securities Health Care Conference

ERASErasca2026-04-27 20:01 EST

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Stock data

Close
18.87 USD
Market cap
4.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States